Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers
Yıl: 2019 Cilt: 15 Sayı: 2 Sayfa Aralığı: 125 - 129 Metin Dili: İngilizce DOI: 10.5152/ejbh.2019.4677 İndeks Tarihi: 07-04-2020
Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers
Öz: Objective: Breast cancer is the most common cancer among women worldwide. Adenine thymine-rich interactive domain 1A (ARIDIA) is a tumorsuppressor gene involved in chromatin remodeling and it encodes the ARIDIA protein. Recent studies have shown the loss of ARIDIA proteinexpression in different carcinomas may have a prognostic significance. In the present study, we aimed to evaluate the interactions between ARIDIAloss and molecular subtypes of breast carcinomas.Materials and Methods: ARIDIA expressions were studied in 292 formalin- fixed, paraffin- embedded breast carcinoma specimens and its associationwith different pathological and clinical parameters was evaluated.Results: Loss of ARIDIA expression was detected in 123 cases. There was no statistically significant association between ARID-1A expression andmolecular subtype of breast carcinomas (p=0.110) or HER2 amplification (p=0.909). Contrarily, there was a significant association between ARIDIAexpression and presence of estrogen (p=0.047) or progesterone receptors (p=0.023). Besides a statistically significant relationship was found betweenloss of ARID1A, and the presence of both in situ component (p=0.016) and lymph node metastasis (p=0.001).Conclusion: In this study, we have demonstrated that loss of ARID1A expression positively correlates with hormone receptor status as well astumor aggressiveness.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Akoz G, Diniz G, Ekmekci S, Ekin ZY, Uncel M. Evaluation of human epididymal secretory protein 4 expression according to the molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor 2-positive, triple-negative) of breast cancer. Indian J Pathol Microbiol 2018; 61: 323-329. [CrossRef]
- 2. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008; 359: 2143-53. (PMID: 19005198) [CrossRef]
- 3. Youlken DR, Cramb SM, Dunn NAM, Muller JM, Pyke CM, Baade PD. The Descriptive epidemiology of female breast cancer: An international comprasion of screening, incidence, survival and mortality. Cancer Epidemiology 2012; 36: 237-248. (PMID: 22459198) [CrossRef]
- 4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752. (PMID: 10963602) [CrossRef]
- 5. Wesolowski R, Ramaswamy B. Gene expression profiling: changing face of breast cancer classification and management. Gene Expr 2011; 15: 105-115. (PMID: 22268293) [CrossRef]
- 6. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol 2014; 5: 412-424. (PMID: 25114856) [CrossRef]
- 7. de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2010; 119: 119-126. (PMID: 19669409) [CrossRef]
- 8. Allo G, Bernardini MQ, Wu RC, Shih IeM, Kalloger S, Pollett A, Gilks CB, Clarke BA. ARID1A los correlates with missmatch reparir defiency and intact p53 expression in high grade endometrial carcinomas. Mod Pathol 2014; 27: 255-261. (PMID: 23887303) [CrossRef]
- 9. Solakoglu Kahraman D, Diniz G, Sayhan S, Ayaz D, Uncel M, Karadeniz T, Akman T, Ozdemir A. Differences in the ARID-1 alpha expressions in squamous and adenosquamous carcinomas of uterine cervix. APMIS 2015; 123: 847-850. (PMID: 26303865) [CrossRef]
- 10. Takeda T, Banno K, Okawa R, Yanokura M, Iijima M, Irie-Kunitomi H, Nakamura K, Iida M, Adachi M, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D. ARID1A gene mutation in ovarian and endometrial cancers. Oncology Rep 2016; 35: 607-613. (PMID: 26572704) [CrossRef]
- 11. Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ, Huntsman DG, Clarke B, Schaeffer DF. ARID1A/Baf250a as a prognostic marker for gastric carcinoma: A study of 2 cohorts. Hum Pathol 2014; 45: 1258-1268. (PMID: 24767857) [CrossRef]
- 12. Zhao J, Liu C, Zhao Z. ARID1A: a potential prognostic factor for breast cancer. Tumour Biol 2014; 35: 4813-4819. (PMID: 24430365) [CrossRef]
- 13. Wang DD, Chen YB, Pan K, Wang W, Chen SP, Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, He J, Xia JC. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One 2012; 7: e40364. (PMID: 22808142) [CrossRef]
- 14. Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst 2014; 106: pii: dju165. (PMID: 25118203) [CrossRef]
- 15. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma. Mod Pathol 2004; 17: 646-652. (PMID: 15073596) [CrossRef]
- 16. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348: 2339-2347. (PMID: 12788999) [CrossRef]
- 17. Ignatiadis M, Bedard P, HaibeKains B, Singhal S, Loi S, Criscitiello C, et al. A meta analysis of gene expression profiling studies identifies clinically relevant oncogenic pathways in basal like breast cancer. Cancer Res 2009; 69: 106. [CrossRef]
- 18. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 2011; 13: 221. (PMID: 22217398) [CrossRef]
- 19. Fu X, Osborne CK, Schiff R. Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast 2013; 22(Suppl 2): S12-S18. (PMID: 24011769) [CrossRef]
- 20. Putti TC, El-Rehim DMA, Rakha EA, Paish CE, Lee AHS, Pinder SE, Ellis IO. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005; 18: 26-35. (PMID: 15332092) [CrossRef]
- 21. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007; 26: 6469-6487. (PMID: 17471238) [CrossRef]
- 22. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y. Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. Am J Surg 2003; 185: 165-167. (PMID: 12559449) [CrossRef]
| APA | ÜNÇEL M, DİNİZ ÜNLÜ A, AKÖZ G, YILDIRIM EKİN Z, Sayhan S, YARDIM S, Salimoğlu S (2019). Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. , 125 - 129. 10.5152/ejbh.2019.4677 |
| Chicago | ÜNÇEL Melek,DİNİZ ÜNLÜ AYŞE GÜLDEN,AKÖZ Gamze,YILDIRIM EKİN Zübeyde,Sayhan Sevil,YARDIM Serdar,Salimoğlu Semra Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. (2019): 125 - 129. 10.5152/ejbh.2019.4677 |
| MLA | ÜNÇEL Melek,DİNİZ ÜNLÜ AYŞE GÜLDEN,AKÖZ Gamze,YILDIRIM EKİN Zübeyde,Sayhan Sevil,YARDIM Serdar,Salimoğlu Semra Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. , 2019, ss.125 - 129. 10.5152/ejbh.2019.4677 |
| AMA | ÜNÇEL M,DİNİZ ÜNLÜ A,AKÖZ G,YILDIRIM EKİN Z,Sayhan S,YARDIM S,Salimoğlu S Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. . 2019; 125 - 129. 10.5152/ejbh.2019.4677 |
| Vancouver | ÜNÇEL M,DİNİZ ÜNLÜ A,AKÖZ G,YILDIRIM EKİN Z,Sayhan S,YARDIM S,Salimoğlu S Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. . 2019; 125 - 129. 10.5152/ejbh.2019.4677 |
| IEEE | ÜNÇEL M,DİNİZ ÜNLÜ A,AKÖZ G,YILDIRIM EKİN Z,Sayhan S,YARDIM S,Salimoğlu S "Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers." , ss.125 - 129, 2019. 10.5152/ejbh.2019.4677 |
| ISNAD | ÜNÇEL, Melek vd. "Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers". (2019), 125-129. https://doi.org/10.5152/ejbh.2019.4677 |
| APA | ÜNÇEL M, DİNİZ ÜNLÜ A, AKÖZ G, YILDIRIM EKİN Z, Sayhan S, YARDIM S, Salimoğlu S (2019). Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. European Journal of Breast Health, 15(2), 125 - 129. 10.5152/ejbh.2019.4677 |
| Chicago | ÜNÇEL Melek,DİNİZ ÜNLÜ AYŞE GÜLDEN,AKÖZ Gamze,YILDIRIM EKİN Zübeyde,Sayhan Sevil,YARDIM Serdar,Salimoğlu Semra Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. European Journal of Breast Health 15, no.2 (2019): 125 - 129. 10.5152/ejbh.2019.4677 |
| MLA | ÜNÇEL Melek,DİNİZ ÜNLÜ AYŞE GÜLDEN,AKÖZ Gamze,YILDIRIM EKİN Zübeyde,Sayhan Sevil,YARDIM Serdar,Salimoğlu Semra Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. European Journal of Breast Health, vol.15, no.2, 2019, ss.125 - 129. 10.5152/ejbh.2019.4677 |
| AMA | ÜNÇEL M,DİNİZ ÜNLÜ A,AKÖZ G,YILDIRIM EKİN Z,Sayhan S,YARDIM S,Salimoğlu S Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. European Journal of Breast Health. 2019; 15(2): 125 - 129. 10.5152/ejbh.2019.4677 |
| Vancouver | ÜNÇEL M,DİNİZ ÜNLÜ A,AKÖZ G,YILDIRIM EKİN Z,Sayhan S,YARDIM S,Salimoğlu S Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. European Journal of Breast Health. 2019; 15(2): 125 - 129. 10.5152/ejbh.2019.4677 |
| IEEE | ÜNÇEL M,DİNİZ ÜNLÜ A,AKÖZ G,YILDIRIM EKİN Z,Sayhan S,YARDIM S,Salimoğlu S "Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers." European Journal of Breast Health, 15, ss.125 - 129, 2019. 10.5152/ejbh.2019.4677 |
| ISNAD | ÜNÇEL, Melek vd. "Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers". European Journal of Breast Health 15/2 (2019), 125-129. https://doi.org/10.5152/ejbh.2019.4677 |
